Trial
NCT04172844
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Medical College of Wisconsin
Collaborators
—
Condition
Acute Myelogenous Leukemia
Intervention
Azacitidine
Why stopped
Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no regulatory path forward for pevonedistat.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-04